ongo
threat
pose
circul
zoonot
strain
new
strategi
requir
prepar
next
emerg
coronaviru
cov
previous
group
target
conserv
coronaviru
protein
strategi
gener
liveattenu
vaccin
strain
current
futur
cov
mind
explor
whether
manipul
cov
conserv
methyltransferas
mtase
could
provid
broad
attenu
platform
futur
emerg
strain
use
sarscov
mous
model
mutant
vaccin
evalu
protect
heterolog
challeng
efficaci
age
host
potenti
revers
pathogenesi
despit
success
concern
virul
age
potenti
revers
make
target
alon
unten
approach
howev
combin
mtase
mutat
previous
describ
cov
fidel
mutant
produc
vaccin
strain
capabl
protect
heterolog
viru
challeng
efficaci
age
mice
evid
revers
togeth
result
indic
target
cov
mtase
parallel
conserv
attenu
mutat
may
provid
platform
strategi
rapidli
gener
liveattenu
coronaviru
vaccin
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
attenu
major
compon
futur
liveattenu
coronaviru
vaccin
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
howev
broad
conserv
coupl
robust
viral
yield
permit
use
combin
anoth
attenu
mutat
exonucleas
exon
activ
target
conserv
coronaviru
activ
produc
stabl
attenu
viru
capabl
protect
heterolog
challeng
efficaci
age
mice
absenc
revers
immunocompromis
model
togeth
result
indic
target
coronaviru
may
critic
compon
futur
live
attenu
coronaviru
vaccin
approach
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
sarscov
induc
sever
weight
loss
fail
recov
sever
succumb
infect
fig
notabl
sar
mutant
induc
weight
loss
mice
recov
infect
diverg
wildtyp
infect
day
post
infect
examin
viral
replic
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
result
indic
attenu
mtase
sarscov
mutant
capabl
induc
robust
protect
zoonot
group
spike
viru
term
diseas
weight
loss
data
viral
lung
titer
hemorrhag
score
indic
littl
diseas
mice
vaccin
compar
mock
vaccin
mice
fig
importantli
equival
neutral
wildtyp
sarscov
sera
mice
abl
effect
block
chimer
viru
like
contribut
protect
emerg
coronavirus
remain
signific
threat
global
public
health
rapid
respons
vaccin
platform
need
stem
futur
outbreak
howev
failur
mani
previou
cov
vaccin
formul
clearli
highlight
need
test
efficaci
differ
condit
especi
vulner
popul
like
age
immunecompromis
studi
illustr
despit
success
young
model
mutant
carri
much
risk
pathogenesi
revers
vulner
model
use
standalon
vaccin
strategi
importantli
mutat
pair
attenu
approach
provid
robust
protect
heterolog
challeng
vulner
popul
coupl
increas
safeti
reduc
pathogenesi
studi
highlight
potenti
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
begin
centuri
signal
new
era
emerg
viral
diseas
sinc
dozen
virus
emerg
anim
popul
produc
signific
outbreak
human
transfer
zoonot
pathogen
remain
major
threat
global
public
health
decad
sarscov
infect
middl
east
respiratori
syndrom
coronaviru
cov
continu
period
reintroduct
still
occur
six
year
initi
discoveri
coupl
recent
discov
sarsand
merslik
coronavirus
circul
anim
popul
threat
coronaviru
fuel
outbreak
remain
far
remot
mind
strategi
must
develop
rapidli
respond
potenti
cov
emerg
reemerg
event
sarsand
lesser
extent
merscov
outbreak
mostli
contain
limit
primarili
due
effect
public
health
measur
delay
transmiss
virus
symptomat
diseas
standard
antivir
treatment
type
ifn
tradit
nucleosid
analog
like
ribavirin
shown
minim
success
either
epidem
strain
sever
antibodi
design
sarsand
merscov
efficaci
found
strain
specif
may
offer
minim
protect
heterolog
unrel
coronavirus
especi
therapeut
condit
drug
target
conserv
cov
activ
either
margin
efficaci
vivo
offer
small
window
treatment
earli
infect
similar
viral
infect
effect
treatment
coronavirus
prevent
via
vaccin
context
sarsand
merscov
outbreak
wealth
vaccin
strategi
develop
examin
mani
util
subunit
base
approach
other
use
viru
like
particl
vector
system
induc
immun
less
desir
commerci
safeti
reason
number
live
attenu
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
strain
also
develop
target
conserv
cov
element
specif
approach
may
strain
group
depend
mani
vaccin
approach
protect
homolog
challeng
note
follow
vivo
vaccin
young
anim
howev
failur
noninfecti
vaccin
regard
heterolog
challeng
age
mice
signal
major
issu
use
vulner
popul
impact
coronaviru
diseas
manuscript
expand
upon
liveattenu
vaccin
approach
base
mutat
coronaviru
methyltransferas
previou
work
murin
hepat
viru
sarscov
merscov
found
disrupt
activ
render
attenu
strain
sensit
activ
interferon
stimul
work
group
went
show
mutant
provid
protect
lethal
challeng
sarscov
merscov
young
anim
work
set
forth
evalu
attenu
platform
strategi
liveattenu
coronaviru
vaccin
use
model
explor
heterolog
challeng
efficaci
age
potenti
revers
found
mutant
alon
suffici
attenu
use
univers
previou
liveattenu
coronaviru
platform
taken
advantag
need
conserv
exonucleas
exon
coronaviru
envelop
e
protein
similar
exon
mtase
signific
homolog
across
coronaviru
famili
cov
envelop
protein
fig
importantli
critic
kdke
enzymat
motif
highli
conserv
allow
predict
disrupt
mtase
function
earli
host
respons
sarscov
mutant
equival
wildtyp
infect
unlik
exon
e
protein
mutant
coronavirus
demonstr
signific
attenu
term
viral
replic
vitro
except
context
type
ifn
pretreat
similarli
vivo
character
found
deficit
viral
replic
earli
time
day
mark
attenu
late
time
post
infect
result
suggest
earli
portion
infect
equival
wildtyp
viru
infect
explor
question
util
system
biolog
approach
compar
wildtyp
mutant
old
mice
model
mice
infect
mouseadapt
mutant
discern
attenu
day
fig
howev
day
reduct
replic
observ
lung
infect
mice
correspond
kinet
interferon
stimul
gene
isg
express
importantli
global
host
express
respons
model
trend
pca
plot
total
rna
express
find
type
mutant
viru
profil
cluster
togeth
day
fig
monitor
day
subsequ
challeng
chimer
strain
follow
vaccin
fig
togeth
data
indic
liveattenu
vaccin
suffici
capac
protect
heterolog
cov
challeng
young
mice
low
dose
vaccin
provid
protect
age
mice
high
rate
mortal
age
popul
repres
vulner
group
need
effect
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
absenc
detect
viral
replic
day
fig
togeth
result
indic
mutant
harbor
risk
pathogen
high
dose
also
provid
age
mice
robust
protect
lethal
challeng
mutant
revert
immunecompromis
model
despit
import
caveat
mutant
demonstr
efficaci
vaccin
follow
heterolog
challeng
age
model
sarscov
diseas
howev
revers
adapt
live
attenu
strain
repres
signific
concern
use
viabil
multipl
mechan
liveattenu
vaccin
concern
revers
potenti
virul
liveattenu
vaccin
platform
target
activ
limit
dire
circumst
one
possibl
expand
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
control
fig
importantli
sera
vaccin
mice
capabl
neutral
wt
sarscov
well
chimer
spike
viru
fig
equival
neutral
induc
mutant
fig
result
indic
doubl
mutant
vaccin
provid
robust
protect
homolog
heterolog
challeng
address
heterolog
challeng
efficaci
age
model
next
examin
mutat
revers
potenti
similar
origin
mutant
show
signific
diseas
rag
mice
acut
infect
day
mice
euthan
lung
tissu
harvest
homogen
clarifi
use
infect
old
balbc
mice
contrast
fig
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
weight
loss
lethal
upon
acut
infect
fig
examin
input
viral
titer
reveal
absenc
detect
viru
five
rag
mice
infect
mutant
fig
result
indic
follow
vivo
replic
day
mutant
fail
revert
virul
form
addit
result
suggest
doubl
mutant
could
clear
immun
compromis
mice
without
need
tradit
adapt
immun
togeth
data
argu
mutant
unlik
revert
even
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
threat
zoonot
coronavirus
stem
potenti
emerg
also
lack
effect
strategi
combat
epidem
coronaviru
diseas
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
cost
higher
virul
potenti
revers
thu
limit
use
dire
situat
given
risk
associ
mutat
singl
target
attenu
platform
evalu
way
increas
safeti
without
sacrif
vaccin
efficaci
first
consid
rna
isol
microarray
process
identif
differenti
express
rna
isol
microarray
process
qualiti
control
normal
whole
lung
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
homogen
carri
previous
describ
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
determin
describ
previous
ccbyncnd
intern
licens
made
avail
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
authorfund
http
doi
biorxiv
preprint
